Grant & Award Recipients

Below is a list of grant and award recipients. You may narrow the list down by using the filters below. The list can be sorted by year, last name, and institution. The institution listed reflects the sponsoring institution at the time of grant or award.

View All Recipients

Year First Name Last Name Degree Institution Title Grant Amount ($)
2018 Rajiv Agarwal MD Memorial Sloan Kettering Cancer Center Evaluating the Impact of Proactive Palliative Care in Patients Initiating Phase I Targeted or Immune-Based Cancer Therapeutics: A Randomized Controlled Trial 50,000.00
2018 David Aggen MD, PhD Columbia University Targeting Myeloid-Derived Suppressor Cells in Renal Cell Cancer with Combination IL-1 Beta and PD-1 Blockade 50,000.00
2018 Kathryn Arbour MD Memorial Sloan Kettering Cancer Center Combination MEK and FGFR-1 Inhibition in KRAS-mutant NSCLC: A Phase I Dose Escalation Trial of Trametinib and Ponatinib 50,000.00
2018 Marina Baretti MD Johns Hopkins University A Phase 2 Clinical Trial of Entinostat in Combination with Nivolumab for Patients with Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma 50,000.00
2018 Allison Betof Warner MD, PhD Memorial Sloan Kettering Cancer Center Exercise Regulation of Immune Activation and Response in Cancer: Implications for Immunotherapy 50,000.00
2018 Andrew Bruggeman MD University of California, San Diego Integration of Palliative Care into the Radiation Oncology Clinic 50,000.00
2018 Zachary Buchwald MD, PhD Emory University The role of the tumor draining lymph node in induction of the abscopal effect 50,000.00
2018 Jad Chahoud MD The University of Texas M.D. Anderson Cancer Center Identification of viral and immune biomarkers for metastasis and poor survival in penile squamous cell carcinoma 50,000.00
2018 Huizi Chen MD, PhD The Ohio State University Research Autopsy for Characterization of Recurrent Small Cell Lung Cancer 50,000.00
2018 Eric Christenson MD Johns Hopkins University Characterizing the Impact of the APOBEC3A-B Deletion in Breast Cancer Development and Probing Therapeutic Vulnerability 50,000.00
2018 Jennifer Crombie MD Dana-Farber Cancer Institute A Phase II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma 50,000.00
2018 Anastasios Dimou MD University of Colorado MHC genotype in shaping the risk for EGFR mutation driven lung cancer 50,000.00
2018 Adam Durbin MD, PhD Dana-Farber Cancer Institute Epigenetic dissection of core-regulatory circuity in rhabdomyosarcoma 50,000.00
2018 Hany Elmariah MD, MS Johns Hopkins University CD8 Depleted, Non-Engrafting, HLA mismatched Unrelated Donor Lymphocyte Infusion for Patients with MDS and Secondary AML 50,000.00
2018 Penny Fang MD, MBA The University of Texas M.D. Anderson Cancer Center Microbiome Profile as a Predictive Biomarker for Cervical Cancer Response to Chemoradiation and Immunotherapy Treatment 50,000.00
2018 Tim Ferng MD University of California, San Francisco Identifying Synthetic Lethal Interactions in FLT3-mutant Acute Myeloid Leukemia Using Dynamic BH3 Profiling 50,000.00
2018 Ana Garrido-Castro MD Dana-Farber Cancer Institute Evaluating the immune landscape of metastatic triple-negative breast cancer and identifying predictive biomarkers of response to PD-1 inhibition 50,000.00
2018 Carl Gay MD, PhD The University of Texas M.D. Anderson Cancer Center Targeting DNA damage response via ATR inhibition to enhance PARP and PD-L1 blockade in small cell lung cancer. 50,000.00
2018 Karthik Giridhar MD Mayo Clinic, Minnesota Comprehensive, serial androgen receptor variant profiling in peripheral blood and metastatic biopsies to identify predictive biomarkers to abiraterone acetate in metastatic castrate resistant prostate cancer. 50,000.00
2018 Colin Godwin MD Fred Hutchinson Cancer Research Center Novel Antibodies to the C2-set Domain of CD33 for Acute Myeloid Leukemia (AML) Immunotherapy 50,000.00
2018 Pedram Heidari MD Massachusetts General Hospital Enhancing anti-tumor effects of immune checkpoint inhibitors with molecular radiotherapy in neuroendocrine neoplasms 50,000.00
2018 Wade Iams MD Northwestern University Understanding dynamic somatic genomic changes and hereditary predisposition in patients with small cell lung cancer 50,000.00
2018 Megan Insco MD, PhD Dana-Farber Cancer Institute Investigating Transcriptional CDK13 in Melanoma 50,000.00
2018 Russell Jenkins MD, PhD Dana-Farber Cancer Institute Effect of EZH2 Inhibition on De-Repression of Endogenous Retroviruses and Response to PD-1 Blockade in Melanoma 50,000.00
2018 Allison Kaeding MD Fred Hutchinson Cancer Research Center Validation of Mesothelin as a Novel Disease Marker and Therapeutic Target in Acute Myeloid Leukemia 50,000.00
2018 Tyler Ketterl MD Fred Hutchinson Cancer Research Center Feasibility of a Resistance Training Intervention in Adolescent and Young Adult Hematopoietic Cell Transplant Survivors 50,000.00
2018 Niloufer Khan MD Memorial Sloan Kettering Cancer Center Impact of the intestinal microbiome on outcomes after autologous stem cell transplantation for hematologic malignancies. 50,000.00
2018 Chul Kim MD, MPH Georgetown University Targeting the PD-1/PD-L1 pathway with durvalumab in virus-infected patients with NSCLC 50,000.00
2018 Paul Koller MD The University of Texas M.D. Anderson Cancer Center Defining the function and targeting HIF-2 alpha in Acute Myeloid Leukemia 50,000.00
2018 Andrew Laccetti MD, MS The University of Texas M.D. Anderson Cancer Center Remote monitoring of patient reported outcomes with Fitbit to enable longitudinal predictive modeling in prostate cancer 50,000.00
2018 Lauren Levine MD, MS University of California, San Francisco Defining the Contribution of Systemic Immunity to Effective Tumor Rejection in Advanced Melanoma 50,000.00
2018 Ang Li MD University of Washington Real-World Assessment of Thrombosis in Patients with Multiple Myeloma on Immunomodulatory Drugs (IMID) 50,000.00
2018 Eben Lichtman MD University of North Carolina, Chapel Hill Pre-Clinical Evaluation of B7H3-Specific Chimeric Antigen Receptor T-cells for the Treatment of Acute Myeloid Leukemia 50,000.00
2018 Jessica Lin MD Massachusetts General Hospital Understanding the tumor heterogeneity and evolution of fusion-driven NSCLC 50,000.00
2018 David Liu MD, MPH Dana-Farber Cancer Institute Dissecting Response and Resistance to Immune and Targeted Therapies in Metastatic Melanoma Through Clinical Computational Oncology 50,000.00
2018 Sydney Lu MD, PhD Memorial Sloan Kettering Cancer Center Therapeutic Targeting of RNA Splicing Factor mutant Leukemias via Inhibiting Protein Arginine Methylation 50,000.00
2018 Liam Macleod MD, MPH University of Pittsburgh Quality, Regionalization and Access in Advanced Kidney Cancer 50,000.00
2018 Abhishek Mangaonkar MBBS Mayo Clinic, Minnesota To define the role of aberrant DNA methylation in chronic myelomonocytic leukemia 50,000.00
2018 Steven Maron MD University of Chicago Intra-patient tumor immune environment heterogeneity and immune checkpoint blockade resistance 50,000.00
2018 Kamal Menghrajani MD Memorial Sloan Kettering Cancer Center Histone Methyltransferase Inhibitor (Pinometostat) with Azacitidine Combination Therapy in Patients with Relapsed / Refractory MLL-rearranged Acute Myeloid Leukemia 50,000.00
2018 Douglas Micalizzi MD, PhD Massachusetts General Hospital The Role of the Histone Methyltransferase, NSD1, in Circulating Tumor Cell Survival and Metastasis 50,000.00
2018 Brian Miller MD, PhD Dana-Farber Cancer Institute Dissecting Exhausted T Cell Subpopulations to Improve Anti-PD-1 Treatment of Metastatic Melanoma 50,000.00
2018 Devarati Mitra MD, PhD Dana-Farber Cancer Institute Radiation therapy in immune checkpoint inhibitor resistant head and neck cancer 50,000.00
2018 Ankur Nagaraja MD, PhD Dana-Farber Cancer Institute Targeting the DNA Damage Response in Gastroesophageal Adenocarcinoma 50,000.00
2018 Hong Ha Rosa Nguyen MD St. Jude Children's Research Hospital Optimizing immunotherapy in neuroblastoma and understanding the role of NK cells 50,000.00
2018 Maliha Nusrat MBBS The University of Texas M.D. Anderson Cancer Center Modulation of anti-tumor immune response in colorectal cancer through PI3K-AKT pathway inhibition. 50,000.00
2018 Daniel O'Neil MD, MPH Columbia University Quality of Breast Cancer Care in Five Public Hospitals in South Africa and Effects on Survival 50,000.00
2018 Eileen Parkes MBBS, PhD Queen's University Belfast, United Kingdom Activating the STING immune pathway in combination with anti-PD-1 agents in High Grade Serous Ovarian Cancer 50,000.00
2018 Ravi Patel MD, PhD University of Wisconsin Determining the dose and timing of systemic targeted radiation therapy with dual systemic checkpoint blockade. 50,000.00
2018 Zachary Reitman MD, PhD Dana-Farber Cancer Institute Identifying therapeutic dependencies in PPM1D-mutated diffuse intrinsic pontine glioma 50,000.00